SP-002 with Vismodegib for Advanced Basal Cell Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (SP-002) combined with vismodegib for people with locally advanced basal cell carcinoma, a type of skin cancer that can't be treated with surgery or has come back after surgery. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a single skin cancer (basal cell carcinoma) that is at least 1 cm but not more than 5 cm across, and it is considered locally advanced (spread to nearby areas but not to distant organs)
- Surgery is not a good option for you (either because it would cause too much damage, or because the cancer came back after surgery and more surgery is unlikely to work)
- You are willing to have a small biopsy (3-4 mm) of your tumor before and during the study
- You have adequate blood counts, liver and kidney function (your doctor will check this)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
This study registers people in the Netherlands who have certain types of basal cell skin cancer and take an oral hedgehog-blocking medicine. It may help doctors understand how well these tablets work and how patients do in real life.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This Phase 2 study looks at using a medication that blocks the “Sonic Hedgehog” pathway together with radiotherapy to reduce future problems from locally advanced basal cell carcinoma (BCC). It’s for people whose cancer responded completely to the first Sonic Hedgehog pathway inhibitor treatment and where doctors can confirm that response with a tissue test.
This study looks at how people with advanced basal cell carcinoma (a type of skin cancer that is hard to treat or has spread) are cared for and what happens over time. It does not test any new treatments, but helps doctors learn more about the disease.
This trial tests a combination of blue-light therapy (a type of photodynamic therapy) and an oral medication called sonidegib for people with multiple basal cell carcinomas (BCCs). It may be an option if you have several BCCs that are not suitable for surgery or radiation, or if you prefer not to have surgery.
Hear when a new Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.